ArticleJournal of neuro-oncology2025
Susceptibility- and T2*-weighted MRI features of CNS large B-cell lymphoma in a large single-center cohort: prevalence, patterns, and clinical associations.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Modal Ultrasound-Based Prognostic Model for Diffuse Large B-Cell Lymphoma with Predominantly Superficial Lymph Node Involvement.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe prevalence of susceptibility effects (SE) on T2*-weighted imaging (WI) and susceptibility-WI (SWI) in primary large B-cell lymphoma (IP-LBCL) of the central nervous system (CNS) and diffuse LBCL (DLBCL) with secondary CNS lymphoma (SCNSL) remains debated. This study aimed to clarify SE prevalence and their associations with primary versus secondary manifestations, immune status, corticosteroid treatment, and structural MRI features.
methodsThis retrospective, single-center study included histologically confirmed DLBCL cases (WHO ICD-10 C83.3) with intracerebral involvement (March 2011-November 2023). Subjects without cranial MRI or diagnostic susceptibility-based sequences were excluded. T2*WI and SWI were independently reviewed by two neuroradiologists for presence or absence of SE. Identified SE were classified into five types: punctate, linear, confluent, conglomerate, and/or ring-like. Lesion focality and morphology were assessed on T2WI and contrast-enhanced T1WI. Clinical data included extracranial lymphoma history, immune status, and corticosteroid initiation.
resultsAmong 128 cases (median age: 70 years [58-75]; 65 men), 119 (93%) had IP-LBCL and 9 (7%) had SCNSL. 110 (85.9%) subjects were immunocompetent. T2*WI was available in 90 (70.3%) datasets and SWI in 38 (29.7%). SE detection was higher on SWI (71.1%) than T2*WI (47.8%; P = 0.03). No association was found between SE and lymphoma type (P = 1.00). In IP-LBCL, immunosuppression was significantly associated with SE presence (P = 0.001; OR = 16.1, 95% CI: 2.89-304.79), while age, gender, and corticosteroid use (18.5%) were not. SE showed no significant associations with structural imaging features, including necrosis.
conclusionSE are common in both IP-LBCL and SCNSL, particularly on SWI, and present with variable patterns unrelated to structural MRI features. In IP-LBCL, immunosuppression, but not pre-existing corticosteroid treatment, is significantly associated with the presence of SE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.